JP5519097B2 - 癌を治療するための医薬の製造におけるＰＡＲＰ活性阻害性ＲＮＡｉの使用 - Google Patents

癌を治療するための医薬の製造におけるＰＡＲＰ活性阻害性ＲＮＡｉの使用 Download PDF

Info

Publication number
JP5519097B2
JP5519097B2 JP2006520907A JP2006520907A JP5519097B2 JP 5519097 B2 JP5519097 B2 JP 5519097B2 JP 2006520907 A JP2006520907 A JP 2006520907A JP 2006520907 A JP2006520907 A JP 2006520907A JP 5519097 B2 JP5519097 B2 JP 5519097B2
Authority
JP
Japan
Prior art keywords
cancer
cells
parp
use according
brca2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2006520907A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006528618A5 (enExample
JP2006528618A (ja
Inventor
ヘレデイ，トーマス
Original Assignee
ユニバーシティー オブ シェフィールド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27772701&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5519097(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ユニバーシティー オブ シェフィールド filed Critical ユニバーシティー オブ シェフィールド
Publication of JP2006528618A publication Critical patent/JP2006528618A/ja
Publication of JP2006528618A5 publication Critical patent/JP2006528618A5/ja
Application granted granted Critical
Publication of JP5519097B2 publication Critical patent/JP5519097B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/02—Pentosyltransferases (2.4.2)
    • C12Y204/0203—NAD+ ADP-ribosyltransferase (2.4.2.30), i.e. tankyrase or poly(ADP-ribose) polymerase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Lubricants (AREA)
JP2006520907A 2003-07-25 2004-07-23 癌を治療するための医薬の製造におけるＰＡＲＰ活性阻害性ＲＮＡｉの使用 Expired - Lifetime JP5519097B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0317466.1A GB0317466D0 (en) 2003-07-25 2003-07-25 Use
GB0317466.1 2003-07-25
PCT/GB2004/003235 WO2005012524A1 (en) 2003-07-25 2004-07-23 Use of rnai inhibiting parp activtiy for the manufacture of a medicament for the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011246988A Division JP5547164B2 (ja) 2003-07-25 2011-11-11 癌を治療するための医薬の製造におけるＰＡＲＰ活性阻害性ＲＮＡｉの使用

Publications (3)

Publication Number Publication Date
JP2006528618A JP2006528618A (ja) 2006-12-21
JP2006528618A5 JP2006528618A5 (enExample) 2007-08-02
JP5519097B2 true JP5519097B2 (ja) 2014-06-11

Family

ID=27772701

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2006520907A Expired - Lifetime JP5519097B2 (ja) 2003-07-25 2004-07-23 癌を治療するための医薬の製造におけるＰＡＲＰ活性阻害性ＲＮＡｉの使用
JP2011246988A Expired - Lifetime JP5547164B2 (ja) 2003-07-25 2011-11-11 癌を治療するための医薬の製造におけるＰＡＲＰ活性阻害性ＲＮＡｉの使用
JP2013147532A Expired - Lifetime JP5848728B2 (ja) 2003-07-25 2013-07-16 癌を治療するための医薬の製造におけるＰＡＲＰ活性阻害性ＲＮＡｉの使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2011246988A Expired - Lifetime JP5547164B2 (ja) 2003-07-25 2011-11-11 癌を治療するための医薬の製造におけるＰＡＲＰ活性阻害性ＲＮＡｉの使用
JP2013147532A Expired - Lifetime JP5848728B2 (ja) 2003-07-25 2013-07-16 癌を治療するための医薬の製造におけるＰＡＲＰ活性阻害性ＲＮＡｉの使用

Country Status (18)

Country Link
US (5) US8859562B2 (enExample)
EP (1) EP1649017B2 (enExample)
JP (3) JP5519097B2 (enExample)
KR (1) KR101136702B1 (enExample)
CN (3) CN1856572B (enExample)
AT (1) ATE516353T1 (enExample)
AU (1) AU2004261779B2 (enExample)
BR (1) BRPI0412909B1 (enExample)
CA (1) CA2533423C (enExample)
DK (1) DK1649017T4 (enExample)
ES (1) ES2367433T5 (enExample)
GB (2) GB0317466D0 (enExample)
NO (1) NO338398B1 (enExample)
NZ (1) NZ545307A (enExample)
PL (1) PL1649017T5 (enExample)
PT (1) PT1649017E (enExample)
WO (1) WO2005012524A1 (enExample)
ZA (1) ZA200601386B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014001210A (ja) * 2003-07-25 2014-01-09 Univ Of Sheffield 癌を治療するための医薬の製造におけるＰＡＲＰ活性阻害性ＲＮＡｉの使用

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6956035B2 (en) 2001-08-31 2005-10-18 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
CN100398519C (zh) 2003-02-28 2008-07-02 伊诺泰克制药公司 四环苯甲酰胺衍生物及其用法
MXPA06000993A (es) 2003-07-25 2006-08-31 Cancer Rec Tech Ltd Inhbidores triciclicos de parp.
SG150548A1 (en) * 2003-12-01 2009-03-30 Kudos Pharm Ltd Dna damage repair inhibitors for treatment of cancer
WO2006078503A2 (en) * 2005-01-07 2006-07-27 Arqule, Inc. Compositions for modulation of parp and methods for screening for same
CA2595290C (en) 2005-01-19 2013-06-25 Mgi Gp, Inc. Diazabenzo[de]anthracen-3-one compounds and methods for inhibiting parp
RU2007135362A (ru) 2005-02-25 2009-03-27 Инотек Фармасьютикалз Корпорейшн (Us) Тетрациклические амино- и карбоксамидосоединения и способ их применения
CN101316592A (zh) 2005-08-24 2008-12-03 伊诺泰克制药公司 茚并异喹啉酮类似物及其用法
JP2009517403A (ja) * 2005-11-25 2009-04-30 ユニバーシティー オブ メディシン アンド デンティストリー オブ ニュージャージー Ｐａｒｐ−１阻害剤の使用
JP2010506939A (ja) 2006-10-20 2010-03-04 ダナ ファーバー キャンサー インスティテュート，インコーポレイテッド ガンを処置するためのｄｎａ損傷修復阻害剤および方法
PT2099442E (pt) * 2006-12-26 2015-02-10 Pharmacyclics Inc Métodos de utilização de inibidores de histona desacetilase e monitorização de biomarcadores em terapia de combinação
MX2009009183A (es) 2007-02-28 2009-09-07 Inotek Pharmaceuticals Corp Analogos de indenoisoquinolinona y metodos de utilizacion de los mismos.
GB0707556D0 (en) * 2007-04-19 2007-05-30 Isis Innovation Treatment for cancer
JP5335673B2 (ja) 2007-06-20 2013-11-06 学校法人 埼玉医科大学 子宮癌、乳癌、及び膀胱癌の予防乃至治療に好適な二本鎖核酸分子、癌細胞増殖抑制剤、並びに医薬
WO2009027650A1 (en) * 2007-08-24 2009-03-05 The Institute Of Cancer: Royal Cancer Hospital Materials and methods for exploiting synthetic lethality in brca-associated cancers
SI2209375T1 (sl) 2007-10-03 2014-12-31 Eisai Inc. Spojine inhibitorja PARP in metode uporabe
WO2009113579A1 (ja) 2008-03-11 2009-09-17 学校法人埼玉医科大学 癌の予防乃至治療に好適な二本鎖核酸分子、癌細胞増殖抑制剤、並びに医薬
JP2012507010A (ja) * 2008-10-24 2012-03-22 マグナケム インターナショナル ラボラトリーズ， インコーポレイテッド Ｒａｄ９と選択的に相互作用する化合物をスクリーニングするための方法
US8268550B2 (en) * 2009-06-26 2012-09-18 Massachusetts Institute Of Technology Compositions and methods for identification of PARP function, inhibitors, and activators
WO2010151664A2 (en) 2009-06-26 2010-12-29 Massachusetts Institute Of Technology Compositions and methods for treating cancer and modulating stress granule formation
US8435961B2 (en) * 2009-06-26 2013-05-07 Massachusetts Institute Of Technology Methods and compositions for increasing the activity of inhibitory RNA
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
ES2704303T3 (es) 2010-08-24 2019-03-15 Dana Farber Cancer Inst Inc Procedimientos para la predicción de una respuesta contra el cáncer
SG189280A1 (en) * 2010-10-07 2013-05-31 Agency Science Tech & Res Parp-1 inhibitors
MX368261B (es) 2011-07-22 2019-09-25 Pacylex Pharmaceuticals Inc Letalidad sintetica y el tratamiento de cancer.
ES2687024T3 (es) * 2012-02-23 2018-10-23 Children's Medical Center Corporation Procedimientos para predecir la respuesta contra el cáncer
US9359367B2 (en) 2012-07-09 2016-06-07 Lupin Limited Tetrahydroquinazolinone derivatives as PARP inhibitors
EP2986709A4 (en) * 2013-04-16 2017-03-15 University Of Washington Through Its Center For Commercialization Activating an alternative pathway for homology-directed repair to stimulate targeted gene correction and genome engineering
AU2014321200A1 (en) * 2013-09-23 2016-05-05 The University Of Chicago Methods and compositions relating to cancer therapy with DNA damaging agents
EP3102680B1 (en) 2014-02-07 2018-12-19 VIB vzw Inhibition of neat1 for treatment of solid tumors
US9889141B2 (en) * 2014-10-14 2018-02-13 Institute For Cancer Research Combined inhibition of the vitamin D receptor and poly(ADP) ribose polymerase (PARP) in the treatment of cancer
PL3277321T3 (pl) 2015-04-01 2024-11-18 Anaptysbio, Inc. Przeciwciała skierowane przeciwko białku 3 immunoglobuliny limfocytów t i mucyny (tim-3)
EP3325662B1 (en) 2015-07-17 2023-08-30 Pacylex Pharmaceuticals Inc. Epigenetic silencing of nmt2
KR20180059922A (ko) 2015-10-02 2018-06-05 유니버시티 오브 코펜하겐 히스톤 리더 도메인을 차단하는 소분자
DK3653709T3 (da) 2016-02-22 2021-03-08 Caribou Biosciences Inc Fremgangsmåder til modulering af dna-reparationsresultater
MA50677A (fr) * 2016-11-01 2021-07-14 Anaptysbio Inc Anticorps dirigés contre la protéine d'immunoglobuline de lymphocytes t et mucine 3 (tim-3)
AU2018205401B2 (en) 2017-01-09 2025-01-02 Tesaro, Inc. Methods of treating cancer with anti-TIM-3 antibodies
CN107058233A (zh) * 2017-05-03 2017-08-18 上海长海医院 一种减小肿瘤细胞对抗肿瘤药物的耐药性的方法
CN108048465A (zh) * 2017-12-20 2018-05-18 李风玲 一种抑制PARP基因用于治疗乳腺癌的siRNA
US10519136B2 (en) 2017-12-29 2019-12-31 Accutar Biotechnology Dual inhibitors of PARP1 and CDK
AU2019205325A1 (en) 2018-01-05 2020-08-13 Cybrexa 1, Inc. Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
KR20210097124A (ko) 2018-10-30 2021-08-06 리페어 세라퓨틱스 인크. 화합물, 약제 조성물, 및 화합물 제조 방법 및 atr 키나제 억제제로서의 이것들의 사용 방법
PH12021552205A1 (en) * 2019-03-25 2022-06-13 Cyteir Therapeutics Inc Combinations of rad51 and parp inhibitors
BR112022000297A2 (pt) 2019-07-10 2022-03-15 Cybrexa 3 Inc Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos
MX2022000449A (es) 2019-07-10 2022-04-25 Cybrexa 2 Inc Conjugados peptídicos de citotoxinas como terapéuticos.
KR20220035925A (ko) 2019-07-22 2022-03-22 리페어 세라퓨틱스 인크. Atr 키나제 억제제로서의 치환된 2-모르폴리노피리딘 유도체
CN116234803B (zh) 2019-12-23 2026-06-30 冰洲石生物科技公司 用于治疗癌症的雌激素受体降解剂和细胞周期蛋白依赖性激酶抑制剂的组合
ES3014370T3 (en) 2020-04-28 2025-04-22 Rhizen Pharmaceuticals Ag Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
CN114836472A (zh) * 2021-02-01 2022-08-02 中国人民解放军军事科学院军事医学研究院 PARP-1shRNA重组慢病毒载体、该载体稳定转染HaCaT的细胞系及其应用
WO2022215034A1 (en) 2021-04-08 2022-10-13 Rhizen Pharmaceuticals Ag Inhibitors of poly(adp-ribose) polymerase
AU2022276986B2 (en) 2021-05-18 2025-07-03 Onconic Therapeutics Inc. Parp inhibitor-resistant cancer therapeutic agent
WO2023089032A1 (en) * 2021-11-19 2023-05-25 Institut Curie Methods for the treatment of hrd cancer and brca-associated cancer
WO2023201338A1 (en) 2022-04-15 2023-10-19 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a parp inhibitor
EP4532493A1 (en) 2022-06-01 2025-04-09 Ideaya Biosciences, Inc. Thiadiazolyl derivatives as dna polymerase theta inhibitors and uses thereof
WO2024194402A1 (en) * 2023-03-21 2024-09-26 Institut Curie Farnesyl transferase inhibitor for use in methods for the treatment of hrd cancer
EP4683630A1 (en) * 2023-03-21 2026-01-28 Institut Curie Vps4b inhibitor for use in methods for the treatment of hrd cancer
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025183523A1 (ko) * 2024-02-29 2025-09-04 아주대학교 산학협력단 Parp 억제제 감수성 증가 방법
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5484951A (en) 1990-10-19 1996-01-16 Octamer, Incorporated 5-iodo-6-amino-6-nitroso-1,2-benzopyrones useful as cytostatic and antiviral agents
US5098861A (en) 1991-01-08 1992-03-24 Unitrode Corporation Method of processing a semiconductor substrate including silicide bonding
US5464871A (en) 1993-05-12 1995-11-07 Octamer, Inc. Aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents
EP0600831A1 (de) 1992-11-27 1994-06-08 Ciba-Geigy Ag Phthalazinonderivate
GB9404485D0 (en) * 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
WO1999008680A1 (en) * 1997-08-15 1999-02-25 The Johns Hopkins University Method of using selective parp inhibitors to prevent or treat neurotoxicity
EP1140936B1 (en) * 1999-01-11 2004-03-17 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(adp-ribose) polymerases
US6635677B2 (en) 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
ECSP003637A (es) * 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
DE10022925A1 (de) 2000-05-11 2001-11-15 Basf Ag Substituierte Indole als PARP-Inhibitoren
HRP20030081A2 (en) * 2000-08-08 2005-02-28 Sanofi-Aventis Benzimidazole derivatives, preparation and therapeutic use thereof
HU228960B1 (hu) 2000-10-30 2013-07-29 Kudos Pharm Ltd Ftalazinon-származékok
WO2002090334A1 (en) 2001-05-08 2002-11-14 Kudos Pharmaceuticals Limited Isoquinolinone derivatives as parp inhibitors
US7072771B2 (en) * 2001-06-07 2006-07-04 University Of Kentucky Research Foundation Selective PARP-1 targeting for designing chemo/radio sensitizing agents
US20030073692A1 (en) 2001-08-07 2003-04-17 Pharmacia & Upjohn S.P.A. Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
AUPS019702A0 (en) 2002-01-29 2002-02-21 Fujisawa Pharmaceutical Co., Ltd. Condensed heterocyclic compounds
US20030229004A1 (en) 2002-03-20 2003-12-11 Pangene Corporation Modulation of tumor cells using BER inhibitors in combination with a sensitizing agent and DSBR inhibitors
DE60335359D1 (de) 2002-04-30 2011-01-27 Kudos Pharm Ltd Phthalazinonderivate
AU2003253906A1 (en) 2002-07-19 2004-02-09 Osteotech, Inc. Chisels and procedure for insertion of spinal implant in a spinal disc space
PL1633724T3 (pl) * 2003-03-12 2011-10-31 Kudos Pharm Ltd Pochodne ftalazynonu
US7176188B2 (en) 2003-05-07 2007-02-13 UniversitéLaval Method of lethally sensitizing human and animal cells
GB0317466D0 (en) * 2003-07-25 2003-08-27 Univ Sheffield Use
MXPA06000993A (es) * 2003-07-25 2006-08-31 Cancer Rec Tech Ltd Inhbidores triciclicos de parp.
SG150548A1 (en) 2003-12-01 2009-03-30 Kudos Pharm Ltd Dna damage repair inhibitors for treatment of cancer

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014001210A (ja) * 2003-07-25 2014-01-09 Univ Of Sheffield 癌を治療するための医薬の製造におけるＰＡＲＰ活性阻害性ＲＮＡｉの使用

Also Published As

Publication number Publication date
DK1649017T3 (da) 2011-10-17
US20220062286A1 (en) 2022-03-03
EP1649017B1 (en) 2011-07-13
GB2419882B (en) 2008-04-09
ES2367433T5 (es) 2014-11-03
JP5848728B2 (ja) 2016-01-27
PT1649017E (pt) 2011-09-30
EP1649017B2 (en) 2014-08-27
CN1856572B (zh) 2013-11-06
NZ545307A (en) 2009-08-28
EP1649017A1 (en) 2006-04-26
BRPI0412909A (pt) 2006-09-26
CN1856313A (zh) 2006-11-01
JP5547164B2 (ja) 2014-07-09
CN1856313B (zh) 2011-01-12
AU2004261779A1 (en) 2005-02-10
CA2533423A1 (en) 2005-02-10
NO338398B1 (no) 2016-08-15
US8859562B2 (en) 2014-10-14
PL1649017T5 (pl) 2015-02-27
AU2004261779B2 (en) 2008-07-24
GB0317466D0 (en) 2003-08-27
US20150005327A1 (en) 2015-01-01
US20070179160A1 (en) 2007-08-02
ATE516353T1 (de) 2011-07-15
JP2012102099A (ja) 2012-05-31
HK1094006A1 (en) 2007-03-16
CA2533423C (en) 2014-07-22
CN102935230A (zh) 2013-02-20
DK1649017T4 (da) 2014-12-01
US20200237762A1 (en) 2020-07-30
KR20060052877A (ko) 2006-05-19
NO20060906L (no) 2006-04-25
BRPI0412909B1 (pt) 2022-04-12
JP2014001210A (ja) 2014-01-09
ZA200601386B (en) 2007-04-25
KR101136702B1 (ko) 2012-04-20
CN1856572A (zh) 2006-11-01
ES2367433T3 (es) 2011-11-03
WO2005012524A1 (en) 2005-02-10
GB2419882A (en) 2006-05-10
CN102935230B (zh) 2016-08-10
JP2006528618A (ja) 2006-12-21
GB0603874D0 (en) 2006-04-05
PL1649017T3 (pl) 2011-12-30
HK1182016A1 (zh) 2013-11-22
US20180000822A1 (en) 2018-01-04

Similar Documents

Publication Publication Date Title
JP5848728B2 (ja) 癌を治療するための医薬の製造におけるＰＡＲＰ活性阻害性ＲＮＡｉの使用
JP5580280B2 (ja) 治療用化合物
MXPA06000953A (es) Uso de arni que inhibe la actividad de parp para la manufactura de un medicamento para el tratamiento de cancer
HK1182016B (en) Use of rnai inhibiting parp activtiy for the manufacture of a medicament for the treatment of cancer
HK1094006B (en) Use of rnai inhibiting parp activtiy for the manufacture of a medicament for the treatment of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070612

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070612

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100511

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100811

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111111

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120123

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20120323

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131007

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131010

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140403

R150 Certificate of patent or registration of utility model

Ref document number: 5519097

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250